公开(公告)号：US08333966B2

公开(公告)日：2012-12-18

申请号：US12678857

申请日：2009-04-11

Applicant: Philip Tan ,  Sandy Alexander Simon ,  William Brady ,  Cecile Morales

Inventor： Philip Tan ,  Sandy Alexander Simon ,  William Brady ,  Cecile Morales

IPC: A61K39/395

CPC classification number: A61K39/39541 ,  A61K31/4184 ,  A61K38/16 ,  A61K39/39558 ,  A61K2039/505 ,  C07K16/2896 ,  C07K16/3061 ,  C07K16/461 ,  C07K2317/24 ,  C07K2317/50

Abstract: The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B cell related autoimmune, inflammatory, or hyperproliferative diseases.

Abstract translation: 本公开内容提供人源化抗CD37小模块化免疫药物（SMIP）分子，以及CD37-特异性结合分子（例如抗CD37SMIP蛋白或抗体）与双功能化学治疗剂（例如苯达莫司汀）的协同组合疗法，其可以 同时或顺序施用，用于治疗或预防B细胞相关的自身免疫性，炎症性或过度增殖性疾病。

公开(公告)号：US20100330089A1

公开(公告)日：2010-12-30

申请号：US12664166

申请日：2008-06-12

Applicant: Nitin K. Damle ,  Lioudmila Tchistiakova ,  Kyriaki Dunussi-Joannopoulos ,  Sandy Alexander Simon ,  William Brady ,  Laura Sue Grosmaire ,  Jeffrey Alan Ledbetter

Inventor： Nitin K. Damle ,  Lioudmila Tchistiakova ,  Kyriaki Dunussi-Joannopoulos ,  Sandy Alexander Simon ,  William Brady ,  Laura Sue Grosmaire ,  Jeffrey Alan Ledbetter

IPC: A61K39/395 ,  C07K16/28 ,  C07H21/00 ,  C12N15/63 ,  C12N5/10 ,  C12P21/02 ,  G01N33/566 ,  A61P37/02 ,  A61P29/00 ,  A61P25/00 ,  A61P35/00

CPC classification number: C07K16/2887 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/53 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2319/00

Abstract: The present invention provides materials and methods for treatment of diseases involving aberrant B-cell activity, using a CD20-specific binding molecule, in particular, antibodies or antigen binding fragment thereof. The compositions disclosed herein is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases.

Abstract translation: 本发明提供了使用CD20特异性结合分子，特别是抗体或其抗原结合片段治疗涉及异常B细胞活性的疾病的材料和方法。 本文公开的组合物可用于治疗和诊断B细胞病症，例如B细胞恶性肿瘤和自身免疫性疾病。

公开(公告)号：US20130195850A1

公开(公告)日：2013-08-01

申请号：US13678128

申请日：2012-11-15

Applicant: Philip TAN ,  Sandy Alexander SIMON ,  Charles G. CERVENY ,  Christy Anne NILSSON ,  William BRADY ,  Jeffrey A. LEDBETTER ,  Martha Susan HAYDEN-LEDBETTER ,  Peter Armstrong THOMPSON ,  Cecile MORALES

Inventor： Philip TAN ,  Sandy Alexander SIMON ,  Charles G. CERVENY ,  Christy Anne NILSSON ,  William BRADY ,  Jeffrey A. LEDBETTER ,  Martha Susan HAYDEN-LEDBETTER ,  Peter Armstrong THOMPSON ,  Cecile MORALES

IPC: C07K16/46

CPC classification number: A61K39/39541 ,  A61K31/4184 ,  A61K38/16 ,  A61K39/39558 ,  A61K2039/505 ,  C07K16/2896 ,  C07K16/3061 ,  C07K16/461 ,  C07K2317/24 ,  C07K2317/50

Abstract: The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B cell related autoimmune, inflammatory, or hyperproliferative diseases.

Abstract translation: 本公开内容提供人源化抗CD37小模块化免疫药物（SMIP）分子，以及CD37-特异性结合分子（例如抗CD37SMIP蛋白或抗体）与双功能化学治疗剂（例如苯达莫司汀）的协同组合疗法，其可以 同时或顺序施用，用于治疗或预防B细胞相关的自身免疫性，炎症性或过度增殖性疾病。

公开(公告)号：US20110171208A1

公开(公告)日：2011-07-14

申请号：US12678857

申请日：2009-04-11

Applicant: Philip Tan ,  Sandy Alexander Simon ,  Charles G. Cerveny ,  Christy Anne Nilsson ,  William Brady ,  Jeffrey A. Ledbetter ,  Martha Susan Hayden-Ledbetter ,  Peter Armstrong Thompson ,  Cecile Morales

Inventor： Philip Tan ,  Sandy Alexander Simon ,  Charles G. Cerveny ,  Christy Anne Nilsson ,  William Brady ,  Jeffrey A. Ledbetter ,  Martha Susan Hayden-Ledbetter ,  Peter Armstrong Thompson ,  Cecile Morales

IPC: A61K39/395 ,  C07K16/00 ,  A61P35/00

CPC classification number: A61K39/39541 ,  A61K31/4184 ,  A61K38/16 ,  A61K39/39558 ,  A61K2039/505 ,  C07K16/2896 ,  C07K16/3061 ,  C07K16/461 ,  C07K2317/24 ,  C07K2317/50

Abstract: The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B cell related autoimmune, inflammatory, or hyperproliferative diseases.

Abstract translation: 本公开内容提供人源化抗CD37小模块化免疫药物（SMIP）分子，以及CD37-特异性结合分子（例如抗CD37SMIP蛋白或抗体）与双功能化学治疗剂（例如苯达莫司汀）的协同组合疗法，其可以 同时或顺序施用，用于治疗或预防B细胞相关的自身免疫性，炎症性或过度增殖性疾病。